CytomX Therapeutics Financials
| CTMX Stock | USD 2.25 0.06 2.60% |
Understanding current and past CytomX Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of CytomX Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in CytomX Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in CytomX Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of CytomX Therapeutics. Check CytomX Therapeutics' Beneish M Score to see the likelihood of CytomX Therapeutics' management manipulating its earnings.
CytomX Therapeutics Stock Summary
CytomX Therapeutics competes with Spero Therapeutics, Instil Bio, NextCure, Assembly Biosciences, and Nuvation Bio. CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California. Cytomx Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 174 people.Specialization | Healthcare, Biotechnology |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US23284F1057 |
| CUSIP | 23284F105 |
| Location | California; U.S.A |
| Business Address | 151 Oyster Point |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.cytomx.com |
| Phone | (650) 515 3185 |
| Currency | USD - US Dollar |
CytomX Therapeutics Key Financial Ratios
CytomX Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining CytomX Therapeutics's current stock value. Our valuation model uses many indicators to compare CytomX Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across CytomX Therapeutics competition to find correlations between indicators driving CytomX Therapeutics's intrinsic value. More Info.CytomX Therapeutics is rated below average in return on equity category among its peers. It is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the CytomX Therapeutics' earnings, one of the primary drivers of an investment's value.CytomX Therapeutics Systematic Risk
CytomX Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. CytomX Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on CytomX Therapeutics correlated with the market. If Beta is less than 0 CytomX Therapeutics generally moves in the opposite direction as compared to the market. If CytomX Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one CytomX Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of CytomX Therapeutics is generally in the same direction as the market. If Beta > 1 CytomX Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as CytomX Therapeutics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of CytomX has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if CytomX Therapeutics' financials are consistent with your investment objective using the following steps:- Review CytomX Therapeutics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand CytomX Therapeutics' liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare CytomX Therapeutics' financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if CytomX Therapeutics' stock is overvalued or undervalued.
CytomX Therapeutics Thematic Clasifications
CytomX Therapeutics is part of Cancer Fighters investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases
This theme covers Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. Get More Thematic Ideas
| Cancer Fighters | View |
CytomX Therapeutics June 27, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of CytomX Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of CytomX Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of CytomX Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing CytomX Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build CytomX Therapeutics's daily price indicators and compare them against related drivers.
| Downside Deviation | 8.13 | |||
| Information Ratio | 0.1706 | |||
| Maximum Drawdown | 145.0 | |||
| Value At Risk | (11.48) | |||
| Potential Upside | 15.09 |
Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.